Surrozen's Inflammatory Bowel Disease Candidate Shows Encouraging Preclinical Action

  • Surrozen Inc SRZN announced that preclinical data from its inflammatory bowel disease (IBD) program, SZN-1326, were presented during the 2021 United European Gastroenterology Week.
  • Related: See Why Surrozen Stock Is Surging On Tuesday.
  • Preclinical data of SZN-1326 showed accelerated epithelial regeneration, barrier repair, and colonic mucosal healing.
  • SZN-1326 repaired the damaged colon epithelium and restored the colon tissue structure. It also reduced the histology severity, inflammatory cytokines in the serum.
  • SZN-1326 also showed superiority to anti-IL12/23p40 and anti-TNF-α antibodies in restoring epithelial integrity and mitigating colitis.
  • Findings exhibited that administration of as little as four doses of 0.3 mg/kg of SZN-1326 starting on day 23 stimulated intestinal epithelial regeneration, induced mucosal healing, and restored the epithelial barrier.
  • SZN-1326 demonstrated that it could be safely administered to non-human primates, with pharmacokinetics suitable for humans.
  • Price Action: SRZN stock closed 4.33% higher at $6.50 during after-hours trading on Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBriefsinflammatory bowel diseasePreclinical Phase
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!